
Ibrance
My Prescription
Payment
Select pharmacy


$13,955.79
Print or send this coupon to your phone
About Ibrance
Drug Details
Palbociclib, commercially known as Ibrance, is a medication designed to treat certain types of advanced or metastatic breast cancer, specifically HR+/HER2- breast cancer. This drug works by inhibiting cyclin-dependent kinases 4 and 6 (CDK 4/6), proteins that can become overactive and lead to the uncontrolled growth of cancer cells. By blocking these proteins, palbociclib effectively slows down the progression of cancer. It is typically administered orally once a day for 21 consecutive days, followed by a 7-day break, repeating this cycle every 28 days. Importantly, palbociclib should be used alongside other treatments that reduce or block estrogen levels in the body. Always consult your healthcare provider for personalized medical advice before starting any new treatment.
Price history for Ibrance
21 Capsules, 100MG
Average retail price for Ibrance
Average SaveHealth price for Ibrance
Our price history data is based on aggregated prescription data collected from participating pharmacies in America. Our prescription data updates daily to reflect the latest price changes. If you notice a missing data point, it means there wasn't sufficient data available to generate a monetary value for that date.
*Retail prices are based on pharmacy claims data, and may not be accurate when we don't have enough claims.
Ibrance dosage forms
| Dosage | Quantity | Price from | Per unit |
|---|---|---|---|
| 75MG | 21 Capsules | $13,955.79 | $664.56 |
| 100MG | 21 Capsules | $13,955.79 | $664.56 |
| 125MG | 21 Capsules | $13,955.79 | $664.56 |
Ibrance FAQs
Ibrance is not considered traditional chemotherapy. It is a targeted therapy known as a CDK4/6 inhibitor, which works by interfering with specific proteins involved in the growth and division of cancer cells. It is often used in combination with other treatments for certain types of breast cancer.
Ibrance is used in the treatment of certain types of breast cancer. It is typically prescribed for hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, often in combination with hormone therapy.
The most common side effect of Ibrance (palbociclib) is neutropenia, which is a decrease in the number of neutrophils, a type of white blood cell important for fighting infections.
Ibrance side effects can vary in duration and intensity among individuals. Some side effects may diminish as the body adjusts to the medication, while others might persist throughout the treatment. Common side effects like fatigue, nausea, and hair thinning may improve over time. However, more serious side effects, such as low blood cell counts, require monitoring and may necessitate medical intervention. It is important for patients to discuss any persistent or concerning side effects with their healthcare provider to manage them effectively.
Yes, Ibrance (palbociclib) is considered a type of targeted cancer therapy, which is a form of chemotherapy. It specifically targets certain proteins in cancer cells to inhibit their growth and proliferation.